-
公开(公告)号：KR20210024432A
公开(公告)日：2021-03-05
申请号：KR1020200105189A
申请日：2020-08-21
Applicant: 이화여자대학교 산학협력단 , 한림대학교 산학협력단
IPC: C07F9/6558 , A61K31/662 , A61P19/00
CPC classification number: C07F9/65586 , A61K31/662 , A61P19/00
Abstract: 본 발명의 신규 mTOR 억제제 화합물은 뼈에 대하여 선택적으로 약물 전달이 가능하며 뼈에서 오랜 기간 서서히 방출될 수 있도록, 골 지향성 리간드를 mTOR 억제 뼈 질환 치료제에 연결한 표적지향성 화합물에 관한 것이다.
-
公开(公告)号：KR1020130075845A
公开(公告)日：2013-07-08
申请号：KR1020110144110
申请日：2011-12-28
Applicant: 한림대학교 산학협력단
IPC: C12N15/12 , A01K67/027
Abstract: PURPOSE: Mcl-1 signal transduction can be easily used for the experiment for the verifying. CONSTITUTION: pCAGIG-Mcl-1 recombination gene the Escherichia coli to the host and it is the keen in the over-producing. The marker gene is the GFP expressed gene and/or the carbenicillin resistance gene. Provided is a method of being characterized by the research about the technology which makes the disease animal model of the brain nerve development step in the embryonic period mouse brain after the injection the pCAGIG-Mcl-1 recombination gene. Animal is the embryonic period (E15.5) mouse.
Abstract translation: 目的：Mcl-1信号转导可用于验证实验。 构成：pCAGIG-Mcl-1重组基因将大肠杆菌转移至宿主，并且是过度生产的热衷。 标记基因是GFP表达基因和/或羧苄青霉素抗性基因。 提供了一种通过对注射pCAGIG-Mcl-1重组基因后的胚胎期小鼠脑中脑神经发育步骤的疾病动物模型的技术的研究的特征。 动物是胚胎期（E15.5）小鼠。
-
公开(公告)号：KR1020120139310A
公开(公告)日：2012-12-27
申请号：KR1020110059045
申请日：2011-06-17
Applicant: 한림대학교 산학협력단
Abstract: PURPOSE: An oral composition containing Lonicera japonica thunberg extract is provided to ensure antibacterial and anti-inflammatory effects and to prevent and treat oral diseases and gingival diseases. CONSTITUTION: An oral composition for preventing and treating periodontal diseases contains 0.1-40 wt% of Lonicera japonica Thunberg extract as an active ingredient. The extract is a 70% ethanol extract, a hexane fraction, a dichloromethane(CH2Cl2) fraction, an ethyl acetate(EtOAc) fraction, a butanol fraction(BuOH) fraction, or a water(H_2O) fraction. The extract has an antibacterial effect against Fusobacterium nucleatum(ATCC 25586), Porphyromonas gingivalis(ATCC 33277), Treponema denticola(ATCC 35405), Tannerella forsythia(ATCC 43037), Aggregatibacter actinomycetemcomitans(ATCC 43718), or Prevotella intermedia(ATCC 25611). [Reference numerals] (AA) Anhuisheng Lonicera japonica Thunberg; (BB,DD,FF) Concentration(μg/ml); (CC) Hubei sheng Lonicera japonica Thunberg; (EE) Dongbei 3 sheng Lonicera japonica Thunberg
Abstract translation: 目的：提供含有金银花thonberg提取物的口服组合物，以确保抗菌和抗炎作用，预防和治疗口腔疾病和牙龈疾病。 构成：用于预防和治疗牙周病的口服组合物含有0.1-40％（重量）的金银花提取物作为有效成分。 提取物是70％乙醇提取物，己烷级分，二氯甲烷（CH 2 Cl 2）馏分，乙酸乙酯（EtOAc）馏分，丁醇馏分（BuOH）馏分或水（H_2O）馏分。 提取物对细菌核细菌（ATCC 25586），牙龈卟啉单胞菌（ATCC 33277），牙髓螺旋菌（ATCC 35405），连翘（ATCC 43037），放线菌放线菌（ATCC 43718）或中间型Prevotella（ATCC 25611）具有抗菌作用。 [参考编号]（AA）安徽胜忍忍忍冬虫Thunberg; （BB，DD，FF）浓度（μg/ ml）; （CC）湖北胜忍忍粳Thunberg; （EE）东北3胜忍者japonica Thunberg
-
公开(公告)号：KR1020120000246A
公开(公告)日：2012-01-02
申请号：KR1020100060503
申请日：2010-06-25
Applicant: 한림대학교 산학협력단
Abstract: PURPOSE: An anti-cancer composition containing Caryophyllaceae plant extract and a food composition containing the same are provided to induce rat-2 fibroblast and B103 apoptosis. CONSTITUTION: An anti-cancer composition contains Melandrium firmum extract as an active ingredient, extracted using water and alcohol of 1-5 carbon atoms at 50-100°C for 30 minutes to 12 hours. The extract is isolated from Melandrium firmum root using 10-95%(v/v) methanol. Melandrium firmum includes Melandrium Apricum, Melandrium Capitarum, or Melandrium Seoulensis. A health food contains the anti-cancer composition and supplementary food and further contains a proper carrier, excipient, and diluent.
Abstract translation: 目的：提供含有Caryophyllaceae植物提取物和含有它们的食品组合物的抗癌组合物，以诱导大鼠-2成纤维细胞和B103细胞凋亡。 构成：抗癌组合物含有Melonrium坚果提取物作为活性成分，使用1-5个碳原子的水和醇在50-100℃下萃取30分钟至12小时。 使用10-95％（v / v）甲醇从Melandrium坚果根分离提取物。 枸杞子包括枸杞，Melonrium Capitarum或Melonrium Seoulensis。 保健食品含有抗癌成分和补充食品，并含有适当的载体，赋形剂和稀释剂。
-
公开(公告)号：KR1020120000240A
公开(公告)日：2012-01-02
申请号：KR1020100060491
申请日：2010-06-25
Applicant: 한림대학교 산학협력단
IPC: A61K36/232 , A61K36/23 , A61P35/00
Abstract: PURPOSE: An anti-cancer composition using Angelica polymorpha root extract is provided to induce B103(neuroblastoma) apoptosis and to ensure anti-cancer effect. CONSTITUTION: An anti-cancer composition contains Angelica polymorpha extract as an active ingredient, which is extracted using water and alcohols of 1-5 carbon atoms. The Angelica polymorpha extract is prepared from Angelica decursiva flowers using 10-95%(v/v) methanol. A method for preparing the anti-cancer composition comprises: a step of preparing dried Angelica polymorpha plants; and a step of extracting the plants at 50-100°C for 1-10 hours to prepare water soluble liquid.
Abstract translation: 目的：提供使用当归多形性根提取物的抗癌成分，诱导B103（神经母细胞瘤）细胞凋亡并确保抗癌作用。 构成：抗癌组合物含有当归多形汉提取物作为活性成分，使用1-5个碳原子的水和醇提取。 使用10-95％（v / v）甲醇，从当归果皮花中制备当归多形汉逊酵素提取物。 制备抗癌组合物的方法包括：制备干燥的当归多形植物植物的步骤; 以及在50-100℃下提取植物1-10小时以制备水溶性液体的步骤。
-
Patent Agency Ranking6.发明公开
公开(公告)号：KR1020130079731A
公开(公告)日：2013-07-11
申请号：KR1020120000394
申请日：2012-01-03
Applicant: 한림대학교 산학협력단
IPC: A01K67/027 , C12N5/10
CPC classification number: A01K67/027 , A01K2217/206
Abstract: PURPOSE: A disease model animal development which includes a human cerebrum heterotopia by using a cerebrum micro-generic injection is provided to be widely used for a research of diseases which includes a human brain heterotopia by using the same. CONSTITUTION: A disease model animal development includes a human cerebrum heterotopia which uses a lysophosphatide receptor over-expression. An embryonic period (E13.5) mouse is provided as an animal which is used for a disease model animal. The above-mentioned method is a research about a technology which develops a disease animal model by injecting a specific gene into a cerebral ventricle.
Abstract translation: 目的：提供一种通过使用大脑微型注射液包括人脑异位症的疾病模型动物发育，被广泛用于包括使用它的人类脑异位症的疾病的研究。 构成：疾病模型动物发育包括使用溶血磷脂受体过表达的人类大脑异位症。 提供胚胎期（E13.5）小鼠作为用于疾病模型动物的动物。 上述方法是关于通过将特定基因注射到脑室中发展疾病动物模型的技术的研究。
-
公开(公告)号：KR1020130061391A
公开(公告)日：2013-06-11
申请号：KR1020110127674
申请日：2011-12-01
Applicant: 한림대학교 산학협력단
Abstract: PURPOSE: An anticancer composition using an active ingredient of a Dianthus chinensis L. var. chinensis extract is provided to be used as an anticancer composition for various diseases, and to be contributed to people's health. CONSTITUTION: An anticancer composition containing a Dianthus chinensis L. var. chinensis extract which is prepared from Dianthus chinensis L. var. chinensis using one or more solvents selected from a group consisting of water and C1-C5 alcohols. The active ingredient of Dianthus chinensis L. var. chinensis extract is prepared using 50-95%(w/v) ethanol. A method for manufacturing the anticancer composition comprises: a step of adding 5-20 times weight of ethanol to Dianthus chinensis L. var. chinensis plants; a step of extracting at 50-100 deg. C for 1-10 hours; and a step of filtering and evaporating the extract. A health functional food composition contains the anticancer composition.
Abstract translation: 目的：使用石竹属活性成分的抗癌成分。 提供中华萃取物作为各种疾病的抗癌成分，为人们的健康作出贡献。 构成：含有石竹属植物的抗癌成分。 中华叶提取物，由石竹属 使用一种或多种选自水和C 1 -C 5醇的溶剂。 石竹的活性成分 使用50-95％（w / v）乙醇制备中华提取物。 制造抗癌组合物的方法包括：向石竹中加入5-20倍重量乙醇的步骤。 中华植物; 在50-100度提取的步骤。 C 1-10小时; 以及过滤和蒸发提取物的步骤。 健康功能食品组合物含有抗癌成分。
-
8.发明公开
公开(公告)号：KR1020150094937A
公开(公告)日：2015-08-20
申请号：KR1020140015862
申请日：2014-02-12
Applicant: 한림대학교 산학협력단
IPC: A61K36/704 , A61K36/70 , A61P35/00
CPC classification number: A61K36/704 , A23V2200/308 , A61K2236/33
Abstract: 본 발명은 쪽(
Persicaria
tinctorium ) 추출물을 유효성분으로 함유하는 뇌종양 예방용 약학 조성물 및 이를 포함하는 건강 기능성 식품 조성물에 관한 것이다.Abstract translation: 本发明涉及用于脑肿瘤预防的药物组合物和含有该组合物的膳食补充剂组合物。 药物组合物包括作为活性成分的Persicaria tinctoria提取物。
-
公开(公告)号：KR1020140086240A
公开(公告)日：2014-07-08
申请号：KR1020120156483
申请日：2012-12-28
Applicant: 한림대학교 산학협력단
CPC classification number: A61K36/36 , A23L33/105 , A23V2002/00 , A23V2200/308
Abstract: The present invention relates to an anticancer agent and a method for producing a health functional food composition including the same, wherein the anticancer agent includes an active ingredient of a caryophyllaceae cowherb (Saponaria vaccaria) seed extract which is a component having a medical action to control the proliferation of brain tumor cells.
Abstract translation: 本发明涉及一种抗癌剂及其制造方法，其中含有该抗癌剂的保健功能性食品组合物，其中，所述抗癌剂包括作为控制药物作用的成分的花椰菜（Saponaria vaccaria）种子提取物的活性成分 脑肿瘤细胞的增殖。
-
公开(公告)号：KR1020130085265A
公开(公告)日：2013-07-29
申请号：KR1020120006301
申请日：2012-01-19
Applicant: 한림대학교 산학협력단
IPC: A01K67/027 , C12N15/63 , C12N15/89
CPC classification number: A01K67/027 , A01K2217/20 , C12N15/63 , C12N15/89
Abstract: PURPOSE: A development of an animal model including human brain tumor by in utero electroporation of a sphingolipid receptor is provided to develop a brain tumor which increases brain pressure and induces various failures. CONSTITUTION: A development of an animal model including human brain tumor uses the overexpression of sphingolipid. A sphingolipid receptor gene expression vector is used when a minute gene infusion technique is used.
Abstract translation: 目的：提供一种包括人类脑肿瘤在内的动物模型，通过在子宫内电穿孔鞘脂受体来开发脑肿瘤，其增加脑压力并引起各种失败。 构成：包括人脑肿瘤在内的动物模型的发展使用鞘脂的过表达。 当使用微小的基因输注技术时，使用鞘脂受体基因表达载体。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.019 seconds)
